Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
277 Leser
Artikel bewerten:
(1)

Uniken Inc: Uniken Introduces Certainty in Your Hand Through Palm Vein Authentication

DUBLIN, May 15, 2024 /PRNewswire/ -- Uniken, a leading provider of security, authentication, and identity verification, announces at the Temenos Community Forum 2024 the release of Palm Vein Authentication for in-branch, rural and inclusive banking on its REL-ID platform. Financial institutions have the need for certainty not only in internet and mobile banking, but also in the physical channel. Now, the same certainty provided by REL-ID on electronic channels, is available in person, without the burden of the consumer needing a device with them. In emerging markets smartphone adoption can be a hurdle and in rural and inclusive banking there is a much larger challenge to deliver banking services with safety, security, and convenience.

Uniken Inc

With the release of palm vein authentication on the REL-ID platform, consumers only need to place their hand above a sensor to authenticate themselves in a full contactless solution. Uniken's mission is to provide certainty in every interaction, and we are once again raising the bar by providing a solution that has the highest level of efficacy and takes fraud to zero with lightning speed and convenience.

Uniken has partnered over the last few years with Fulcrum Biometrics, Inc., a Fujitsu company, to deliver REL-ID Palm Vein Authentication based on Fujitsu's market proven PalmSecure technology. The accuracy levels that Uniken customers will achieve in authenticating individuals' identities far exceed what's available with other biometrics like fingerprints, face, and even the newcomers to the palm-scanning field. With a False Acceptance Rate (FAR) of 0.000001% - that's 1 in 100 million - the solution offers unmatched levels of trust in authentication use cases. Privacy characteristics are amazing and are highly resistant to spoofing methods like impersonation or deepfakes. Fraudsters won't be able to take a photo of the internal vein structure and replicate it with liveness to execute a fraudulent transaction like they may be able to in other palm deployments.

Ken Nosker, CEO of Fulcrum Biometrics, Inc. comments "PalmVein authentication, unlike most other biometrics, is extremely protective of user privacy as it relies on internal biological structures that can only be captured by using specially designed imaging systems. The highly accurate and contactless nature of PalmVein authentication makes it especially attractive in high traffic environments such as financial services, healthcare, and e-government initiatives. We are very excited to partner with Uniken in offering PalmSecure to the global banking community."

Palm vein authentication will be included as part of any full REL-ID license and Uniken is making it available to our global partners, including Temenos, Finacle and NTT Data Solutions for deployment. Customers that have modularized licenses may upgrade to a full license to gain the capability immediately.

Bimal Gandhi, CEO, Uniken, shares "I believe biometrics is clearly the key to authentication in the future - palm vein is another modality we feel is critical to have on the platform. Your clients' identities are in their hands - with or without their devices. Our mission is zero fraud and certainty in identity - I am delighted to deliver that in electronic and physical channels with zero friction. Look for more news about Palm Vein Authentication in the next few months as some of our partners, in stealth mode, are working with us on amazing use cases in other verticals."

About Uniken
Uniken accelerates possibilities for client-centric organizations by creating certainty in identity and security while delivering amazing customer experiences. Uniken serves customers of all sizes, worldwide, across a variety of industries. To date, Uniken has secured over $39 trillion in transaction value across over 45 billion client interactions with zero financial or identity loss. With Uniken, organizations grow their businesses and deliver amazing client experiences in a world where identity is a certainty, not a vulnerability.

About Fulcrum Biometrics, Inc.
Fulcrum Biometrics, Inc. is a leading provider of biometric identification technologies and custom software applications for enhancing identity authentication and management. Fulcrum provides hardware and software solutions for non-profits, commercial organizations, local and national governments and military customers in more than 100 countries worldwide. Fulcrum is headquartered with operations and product development at 16108 University Oak, San Antonio, TX 78249. Fulcrum Biometrics, Inc. is a wholly owned subsidiary of Fujitsu Frontech North America Inc.

PR Contact:
Nancy Jones, Uniken
nancy.jones@uniken.com

Logo - https://mma.prnewswire.com/media/2107571/UNKLogo_LtBlue_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/uniken-introduces-certainty-in-your-hand-through-palm-vein-authentication-302145689.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.